ストックスクリーナーアプリを入手
8.01
3.49%
0.27
アフターアワーズ：
8.04
0.03
+0.37%
前日終値:
$7.74
開ける：
$7.81
24時間の取引高:
1.58M
Relative Volume:
1.18
時価総額：
$1.15B
収益：
$175.51M
当期純損益:
$-78.02M
株価収益率:
-15.11
EPS:
-0.53
ネットキャッシュフロー:
$-34.18M
1週間 パフォーマンス:
-0.74%
1か月 パフォーマンス:
-16.13%
6か月 パフォーマンス:
+37.16%
1年 パフォーマンス:
+1.78%
1日の値動き範囲:
$7.67
$8.03
1週間の範囲:
$7.52
$8.03
52週間の値動き範囲:
$4.71
$10.67
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
名前
Aurinia Pharmaceuticals Inc
セクター
電話
250-744-2487
住所
#140, 14315 - 118 AVENUE, EDMONTON, BC
AUPH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
8.01 | 1.15B | 175.51M | -78.02M | -34.18M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-11-04 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-05-05 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-12-10 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-28 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-01-25 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-05-05 | 開始されました | Cowen | Outperform |
| 2020-01-10 | 開始されました | Jefferies | Buy |
| 2019-12-16 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-03-16 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-02-08 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-10-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-05-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2017-03-22 | 繰り返されました | FBR & Co. | Outperform |
| 2016-12-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2015-05-08 | 開始されました | MLV & Co | Buy |
すべてを表示
Aurinia Pharmaceuticals Inc (AUPH) 最新ニュース
(AUPH) Investment Analysis - Stock Traders Daily
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - MSN
Aurinia: My 2024 Sell Call Was WrongSo I'm Upgrading To 'Hold' In 2025 (NASDAQ:AUPH) - Seeking Alpha
Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail
Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space? - Inkl
AUPH: Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space? - StockNews.com
Barclays PLC Boosts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded by StockNews.com to Strong-Buy Rating - MarketBeat
Long Term Trading Analysis for (AUPH) - Stock Traders Daily
New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights - GlobeNewswire Inc.
Aurinia Pharmaceuticals (NASDAQ:AUPH shareholders incur further losses as stock declines 5.2% this week, taking five-year losses to 57% - Simply Wall St
Franklin Resources Inc. Sells 75,024 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Layoff Tracker: Regeneron Acquisition of Oxular Wipes Out Oxular Workforce - BioSpace
Barclays PLC Acquires 143,072 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals laying off dozens in Montgomery County - The Business Journals
State Street Corp Has $21.59 Million Stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
(AUPH) On The My Stocks Page - Stock Traders Daily
Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 9.6% - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Rating Lowered to "Buy" at StockNews.com - MarketBeat
Charles Schwab Investment Management Inc. Grows Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharma Surges Pre-Market After Director Kevin Tang Discloses $10M Stock Buy: Retail Confidence Spikes - MSN
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Held Back By Insufficient Growth Even After Shares Climb 25% - Simply Wall St
Implied Volatility Surging for Aurinia Pharmaceuticals (AUPH) Stock Options - MSN
Aurinia Pharma stock hits 52-week high at $9.76 - Investing.com
Aurinia Pharma stock hits 52-week high at $9.76 By Investing.com - Investing.com UK
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares - Investing.com India
Kevin Tang buys $10.82 million in Aurinia Pharmaceuticals shares By Investing.com - Investing.com Australia
While institutions own 40% of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), retail investors are its largest shareholders with 52% ownership - Yahoo Finance
We Might See A Profit From Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Soon - Simply Wall St
PDT Partners LLC Buys 130,204 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Algert Global LLC - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $3.33 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - MSN
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - sharewise
(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Position Reduced by GSA Capital Partners LLP - MarketBeat
Aurinia Pharmaceuticals Inc (AUPH) 財務データ
収益
当期純利益
現金流量
EPS
0.65%
4.62%
大文字化:
|
ボリューム (24 時間):